67736-1-Ig

antibody from Proteintech Group

Targeting: PTGES3 cPGES, p23, TEBP

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Data presented on provider website)

Antibody Data

Product number

67736-1-Ig

Provider

Proteintech Group

Product name

PTGES3 antibody

Antibody type

Monoclonal

Description

PTGES3 antibody (Cat. #67736-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, mouse, pig, rat and has been validated for the following applications: IF, WB,ELISA.

Reactivity

Human, Mouse, Rat, Porcine

Host

Mouse

Conjugate

Unconjugated

Isotype

IgG

Antibody clone number

3C11D11

Vial size

20ul, 150ul

References

Submitted references

Integrated Metabolomics and Proteomics to Decipher Simiao Pill Improving Lipid Homeostasis through PTGES3-mediated Arachidonic Acid Metabolism in AIA Model.

Cai Y, Guo S, Lin C, Wang Y, Wang C, Wang Z, Xie D, Guan Y, Qiu S, Dong H, Zhang A
Current pharmaceutical design 2025;31(23):1885-1902

---

FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation Inhibitors.

Bastian K, Orozco-Moreno M, Thomas H, Hodgson K, Visser EA, Rossing E, Pijnenborg JFA, Eerden N, Wilson L, Saravannan H, Hanley O, Grimsley G, Frame F, Peng Z, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Maitland NJ, Heer R, Wang N, Goddard-Borger ED, Guerrero RH, Boltje TJ, Drake RR, Scott E, Elliott DJ, Munkley J
Cancer medicine 2025 May;14(10):e70959

---

RBM14 enhances transcriptional activity of p23 regulating CXCL1 expression to induce lung cancer metastasis.

Zhang W, Peng Y, Zhou M, Qian L, Che Y, Chen J, Zhang W, He C, Qi M, Shu X, Tian M, Tian X, Tian Y, Deng S, Wang Y, Huo X, Yu Z, Ma X
Acta pharmaceutica Sinica. B 2025 Jun;15(6):3059-3072

---

Integrating single-cell RNA-Seq and bulk RNA-Seq data to explore the key role of fatty acid metabolism in hepatocellular carcinoma.

Dai H, Tao X, Shu Y, Liu F, Cheng X, Li X, Shu B, Luo H, Chen X, Cheng Z
Scientific reports 2025 Jan 15;15(1):2077

---

Progressively Diminished Prostaglandin E2 Signaling in Concordance with Increasing Fibrosis in Ectopic Endometrium.

Yi Y, Nie J, Liu X, Guo SW
Reproductive sciences (Thousand Oaks, Calif.) 2025 Apr;32(4):1271-1286

---

The integration of multidisciplinary approaches revealed PTGES3 as a novel drug target for breast cancer treatment.

Yin Q, Ma H, Dong Y, Zhang S, Wang J, Liang J, Mao L, Zeng L, Xiong X, Chen X, Wang J, Zheng X
Journal of translational medicine 2024 Jan 20;22(1):84

---

PTGES3 proteolysis using the liposomal peptide-PROTAC approach.

Liu S, Yuan F, Dong H, Zhang J, Mao X, Liu Y, Li H
Biology direct 2024 Dec 26;19(1):144

---

METTL9-SLC7A11 axis promotes hepatocellular carcinoma progression through ferroptosis inhibition.

Bi F, Qiu Y, Wu Z, Liu S, Zuo D, Huang Z, Li B, Yuan Y, Niu Y, Qiu J
Cell death discovery 2023 Nov 28;9(1):428

---

TRIM21 ameliorates hepatic glucose and lipid metabolic disorders in type 2 diabetes mellitus by ubiquitination of PEPCK1 and FASN.

Zhang K, Yang C, Zhou X, Liang J, Guo J, Li M, Zhang Y, Shao S, Sun P, Li K, Huang J, Chen F, Liang X, Su D
Cellular and molecular life sciences : CMLS 2023 May 30;80(6):168

---

High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.

Gao P, Zou K, Xiao L, Zhou H, Xu X, Zeng Z, Zhang W
International immunopharmacology 2022 Sep;110:108954